Senda Biosciences is committed to bringing life-changing treatments to patients by harnessing nature's code to program human cells-both from within and from outside-for targeted, potent, and tunable medicines. Senda's proprietary platform includes an mRNA engine and the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life-accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines for infectious, genetic, metabolic, and autoimmune diseases, as well as oncology and powering new frontiers for mRNA therapeutics and vaccines and gene-editing and protein-based therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/16/22 | $123,000,000 | Series C |
Alexandria Venture Investments Bluwave Capital Flagship Pioneering Longevity Vision Fund Mayo Clinic Ventures Partners Investment Co. Qatar Investment Authority Samsung Life Science Fund Stage 1 Ventures State of Michigan Retirement System | undisclosed |
